StockData
Adaptive Biotechnologies Corp logo

Adaptive Biotechnologies Corp (ADPT) stock

ADPTNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 12/30
$27.87−1.17 (-4.03%)

Close on Nov 16, 2026Market cap $4.45BP/E –Yield –

Adaptive Biotechnologies total assets

Total assets on the balance sheet at the end of each period.

Adaptive Biotechnologies's total assets was $640.68M at Jun 30, 2026. For fiscal 2025 it was $512.74M, down 4.9% from the year before. The highest annual figure on record is $1.12B in fiscal 2020.

Annual total assets

PeriodPeriod endValueChange
FY2025Dec 31, 2025$512.74M-4.9%
FY2024Dec 31, 2024$539.38M-18.4%
FY2023Dec 31, 2023$661.13M-22.8%
FY2022Dec 31, 2022$856.62M-7.2%
FY2021Dec 31, 2021$923.34M-17.3%
FY2020Dec 31, 2020$1.12B+22.4%
FY2019Dec 31, 2019$912.30M+174.2%
FY2018Dec 31, 2018$332.69M–

Quarterly total assets

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$640.68M+29.0%
Q1 FY2026Mar 31, 2026$505.94M-1.0%
Q4 FY2025Dec 31, 2025$512.74M-4.9%
Q3 FY2025Sep 30, 2025$490.61M-12.2%
Q2 FY2025Jun 30, 2025$496.64M-15.1%
Q1 FY2025Mar 31, 2025$510.85M-17.6%
Q4 FY2024Dec 31, 2024$539.38M-18.4%
Q3 FY2024Sep 30, 2024$558.51M-22.2%
Q2 FY2024Jun 30, 2024$584.87M-23.5%
Q1 FY2024Mar 31, 2024$620.32M-21.6%
Q4 FY2023Dec 31, 2023$661.13M-22.8%
Q3 FY2023Sep 30, 2023$717.68M-18.8%
Q2 FY2023Jun 30, 2023$764.54M-5.2%
Q1 FY2023Mar 31, 2023$791.46M-7.8%
Q4 FY2022Dec 31, 2022$856.62M-7.2%
Q3 FY2022Sep 30, 2022$884.21M-10.9%
Q2 FY2022Jun 30, 2022$806.63M-21.9%
Q1 FY2022Mar 31, 2022$858.19M-20.0%
Q4 FY2021Dec 31, 2021$923.34M-17.3%
Q3 FY2021Sep 30, 2021$992.61M-9.4%
Q2 FY2021Jun 30, 2021$1.03B+20.9%
Q1 FY2021Mar 31, 2021$1.07B+22.5%
Q4 FY2020Dec 31, 2020$1.12B+22.4%
Q3 FY2020Sep 30, 2020$1.10B+19.4%
Q2 FY2020Jun 30, 2020$854.82M+42.1%
Q1 FY2020Mar 31, 2020$874.89M+163.0%
Q4 FY2019Dec 31, 2019$912.30M–
Q3 FY2019Sep 30, 2019$917.39M–
Q2 FY2019Jun 30, 2019$601.40M–
Q4 FY2018Dec 31, 2018$332.69M–

More Adaptive Biotechnologies figures

See a number that looks wrong?